Verona Pharma plc (I9SA) - Total Liabilities
Based on the latest financial reports, Verona Pharma plc (I9SA) has total liabilities worth €294.60 Million EUR (≈ $344.42 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore I9SA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Verona Pharma plc - Total Liabilities Trend (2016–2024)
This chart illustrates how Verona Pharma plc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Verona Pharma plc to measure how efficiently the company converts operating cash flow to free cash.
Verona Pharma plc Competitors by Total Liabilities
The table below lists competitors of Verona Pharma plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
L E Lundbergföretagen AB (publ)
ST:LUND-B
|
Sweden | Skr60.77 Billion |
|
Hella KGaA Hueck & Co
XETRA:HLE
|
Germany | €4.17 Billion |
|
Toro Co
NYSE:TTC
|
USA | $2.28 Billion |
|
Petro Rio S.A.
SA:PRIO3
|
Brazil | R$36.48 Billion |
|
Brenntag SE
F:BNR
|
Germany | €6.28 Billion |
|
Zabka Group S.A.
WAR:ZAB
|
Poland | zł17.19 Billion |
|
Jiangsu Yanghe Brewery Joint-Stock Co Ltd
SHE:002304
|
China | CN¥10.95 Billion |
|
Sirius XM Holding Inc
NASDAQ:SIRI
|
USA | $15.42 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Verona Pharma plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Verona Pharma plc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verona Pharma plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verona Pharma plc (2016–2024)
The table below shows the annual total liabilities of Verona Pharma plc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €269.68 Million ≈ $315.29 Million |
+358.32% |
| 2023-12-31 | €58.84 Million ≈ $68.79 Million |
+102.89% |
| 2022-12-31 | €29.00 Million ≈ $33.91 Million |
-24.83% |
| 2021-12-31 | €38.58 Million ≈ $45.11 Million |
+99.37% |
| 2020-12-31 | €19.35 Million ≈ $22.62 Million |
+30.96% |
| 2019-12-31 | €14.78 Million ≈ $17.28 Million |
+2.81% |
| 2018-12-31 | €14.37 Million ≈ $16.80 Million |
+10.52% |
| 2017-12-31 | €13.00 Million ≈ $15.20 Million |
-9.71% |
| 2016-12-31 | €14.40 Million ≈ $16.84 Million |
-- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more